Erratum: Parathyroid hormone as a marker for metabolic bone disease of prematurity

Moreira, Ana Marina; Swischuk, L. E.; Malloy, Michael H.; Mudd, D.; Blanco, Concepción; Geary, Cara

doi:10.1038/jp.2015.64

Cited by 3 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Dual energy X-ray absorptiometry (DEXA) is the gold-standard method for assessing bone mineral density. 3 Because of the hazard of radiation exposure and the cost involved, DEXA is still being used as a research tool in resource-limited settings. Another promising tool is quantitative ultrasound of bone (QUS) using speed of sound technology.…”

Section: Introductionmentioning

confidence: 99%

Early calcium and phosphorus supplementation in VLBW infants to reduce metabolic bone disease of prematurity: a quality improvement initiative

et al. 2022

View full text Add to dashboard Cite

ObjectiveTo reduce the incidence of metabolic bone disease (MBD) among very low birthweight (VLBW) infants admitted to neonatal intensive care unit from baseline of 35% by 50% over 2 years by implementing a quality improvement (QI) initiative.MethodsA multidisciplinary QI team used evidence-based interventions and the healthcare improvement model to reduce MBD rate in VLBW infants. The specific interventions included routine enteral supplementation of calcium and phosphorus using Human Milk Fortifier (HMF) to expressed breast milk by day 14 of life (Plan/Do/Study/Act (PDSA) cycle 1), parenteral and early enteral supplementation of calcium and phosphorus (PDSA cycles 2 and 3). We included VLBW infants admitted within the study period at birth and excluded babies with congenital malformations, skeletal disorders and those who died before 2 weeks of age. Compliance with adding HMF by day 14, compliance with adding calcium and phosphorus in total parenteral nutrition (TPN) from day 1 of life and compliance with starting HMF when the baby reached 100 mL/kg/day of feeds were used as process indicators. The incidence of MBD was used as an outcome indicator during the study. The incidence of MBD was tracked using the Statistical Process Control methodology.ResultsThe baseline MBD rate in 2015 was 35%. After the first PDSA cycle, 20% developed MBD (p=0.02). The same was sustained for a period of 1 year with the rate of 22%. After the second and third PDSA cycles, there was a drop in the MBD rate to 17%, and sustained for 3 months with 21%.ConclusionImplementation of QI initiatives decreased the MBD rate from 35% to <20%. Early parenteral calcium and phosphorus supplementation in TPN and optimising enteral supplementation with multicomponent fortifiers appear to have significant reduction in the incidence of MBD.

show abstract

Section: Introductionmentioning

confidence: 99%

Early calcium and phosphorus supplementation in VLBW infants to reduce metabolic bone disease of prematurity: a quality improvement initiative

et al. 2022

View full text Add to dashboard Cite

show abstract

Disorders of Calcium and Phosphorus Metabolism

Eitel¹,

Koves²,

Ness³

et al. 2024

Avery's Diseases of the Newborn

View full text Add to dashboard Cite

New diagnostic modalities and emerging treatments for neonatal bone disease

Borg

Bishop

2018

Early Human Development

View full text Add to dashboard Cite

Bone disease in the neonatal period has often been regarded as an issue affecting premature infants, or a collection of rare and ultra-rare disorders that most neonatologists will see only once or twice each year, or possibly each decade. The emergence of targeted therapies for some of these rare disorders means that neonatologists may be faced with diagnostic dilemmas that need a rapid solution in order to access management options that did not previously exist. The diagnostic modalities available to the neonatologist have not changed a great deal in recent years; blood tests and radiographs still form the mainstays with other techniques usually reserved for research studies, but rapid access to genomic testing is emergent. This paper provides an update around diagnosis and management of bone problems likely to present to the neonatologist.

show abstract

Erratum: Parathyroid hormone as a marker for metabolic bone disease of prematurity

Abstract: Throughout the text, the units for concentrations of parathyroid hormone were incorrectly presented as mg dl − 1 . The correct unit is pg ml − 1 . The authors regret the error.

Cited by 3 publications

References 0 publications

Early calcium and phosphorus supplementation in VLBW infants to reduce metabolic bone disease of prematurity: a quality improvement initiative

Early calcium and phosphorus supplementation in VLBW infants to reduce metabolic bone disease of prematurity: a quality improvement initiative

Disorders of Calcium and Phosphorus Metabolism

New diagnostic modalities and emerging treatments for neonatal bone disease

Contact Info

Product

Resources

About